Summary

for people ages 18 years and up (full criteria)
at Sacramento, California
study started
estimated completion

Description

Summary

This study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.

Official Title

Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate

Details

Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify because anticoagulation provides a 66% risk reduction in recurrent stroke. However, opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and therefore not detected at the time of stroke. In addition, even when AF is identified anticoagulation may not be initiated due to perceived contraindications.

This study will (1) evaluate whether a gene marker can improve the identification of AF in patients with ischemic stroke, and (2) evaluate decisions by health care provider and patients to anticoagulate AF, and whether this decision could be improved by a marker of AF at time of stroke. An AF Gene Score will be developed comprised of genes associated with inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid identification of stroke due to AF which may increase initiation of anticoagulation therapy. This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty regarding the association of delayed AF with initial stroke and delays anticoagulation.

Keywords

Stroke Atrial Fibrillation Atrial fibrillation stroke

Eligibility

You can join if…

Open to people ages 18 years and up

  • Ischemic stroke within 72 hours of onset
  • Complete evaluation to determine cause of stroke
  • Informed Consent

You CAN'T join if...

  • Active Infection
  • Lymphoma / Leukemia / Blood dyscrasia
  • Hemorrhagic stroke
  • Immunosuppressive therapy
  • Illicit drug use
  • Blood transfusion +/- 1 month
  • Major surgery/trauma in last 6mts

Location

  • University of California Davis accepting new patients
    Sacramento California 95817 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
Links
Sign up for this study
ID
NCT02734758
Study Type
Observational
Last Updated